SCHEMBL6216319

SCHEMBL6216319

Cc1cc2nc(C)c(-c3ccccc3)nc2cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.62
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 3/20 0.56
PDE10A Q9Y233 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NQO2 P16083 1/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
PDGFRB P09619 1/20 0.53
KDR P35968 1/20 0.53
FLT3 P36888 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
KMT2A Q03164 2/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
ATM Q13315 1/20 0.47
TLR9 Q9NR96 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28043991 0.90 KDM4E (0.68) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL30771455 0.90 KDM4E (0.68) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL7690918 0.88 ALDH1A1 (0.56) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL12553478 0.88 ERBB2 (0.66) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL1302744 0.86 ERBB2 (0.64) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL31135158 0.85 TDP1 (0.67) KDM4EALDH1A1PDE10AL3MBTL1TDP1
SCHEMBL923856 0.85 TDP1 (0.67) KDM4EALDH1A1PDE10AL3MBTL1TDP1
SCHEMBL13017481 0.83 KDM4E (0.83) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL19655091 0.83 L3MBTL1 (0.61) ERBB2KDM4EALDH1A1PDE10AL3MBTL1
SCHEMBL19655100 0.83 L3MBTL1 (0.61) ERBB2KDM4EALDH1A1PDE10AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217737-B2 Method and compositions for inhibiting cell proliferative disorders YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2007-05-15 US disclosed
EP-0748219-B8 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-06-08 EP disclosed
EP-0748219-B1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-04-06 EP disclosed
US-5981569-A CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-09 US disclosed
EP-0748219-A4 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 1999-06-16 EP disclosed
US-5849742-A Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis SUGEN INC. (US) 1998-12-15 US disclosed
US-5792771-A FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA SUGEN, INC. (US) 1998-08-11 US disclosed
US-5763441-A ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS SUGEN, INC. (US) 1998-06-09 US disclosed
US-5712395-A BENZO(G)QUINOXALINE YISSUM RESEARCH DEVELOPMENT CORP. (IL) 1998-01-27 US disclosed
EP-0748219-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS Sugen, Inc. (US) 1996-12-18 EP disclosed
WO-1995021613-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN, INC. (US) 1995-08-17 WO disclosed